Related Experiment Videos
Pulmonary Alveolar Proteinosis: recent advances
Peter J Mazzone1, Mary Jane Thomassen, Mani S Kavuru
1Department of Pulmonary & Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
Summary
Pulmonary Alveolar Proteinosis (PAP) may be an autoimmune disease. Autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) are found in patients, suggesting new diagnostic and therapeutic approaches.
Area of Science:
- Pulmonary Medicine
- Immunology
- Genetics
Background:
- Pulmonary Alveolar Proteinosis (PAP) is a rare lung disease characterized by surfactant accumulation.
- Current treatment, whole lung lavage, is not curative and lacks specificity.
- Recent research has uncovered potential autoimmune mechanisms and novel therapeutic targets.
Purpose of the Study:
- To investigate the role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in PAP pathogenesis.
- To explore the potential of GM-CSF autoantibodies as a diagnostic marker.
- To identify new therapeutic strategies for PAP.
Main Methods:
- Generation and study of GM-CSF gene-disrupted mice exhibiting PAP-like lung lesions.
- Analysis of bronchoalveolar lavage fluid and serum from PAP patients for GM-CSF autoantibodies.
- Review of existing literature and preliminary data on GM-CSF therapy.
Main Results:
- GM-CSF knockout mice developed lung pathology mimicking human PAP.
- Biochemical analysis showed similarities between mouse and human PAP material.
- Neutralizing autoantibodies against GM-CSF were detected in idiopathic PAP patients.
- Exogenous GM-CSF showed potential therapeutic benefits in some patients.
Conclusions:
- PAP, particularly the idiopathic form, may be an autoimmune disorder driven by GM-CSF antibodies.
- GM-CSF autoantibodies show promise as a diagnostic biomarker for PAP.
- Targeting GM-CSF deficiency or antibody levels offers potential new therapeutic avenues for PAP.